Syndax Pharmaceuticals (SNDX) Tops Q1 EPS by 26c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.98), $0.26 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $20.04 million versus the consensus estimate of $14.84 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Citi Starts Banco Mercantil do Brasil (BMEB4:BZ) at Buy
• JPMorgan Double Upgrades Hemnet Group AB (HEM:SS) to Overweight